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Available online 26 April 2016Genome-wide association studies (GWAS) point to regions with associated genetic variants but rarely to a
speciﬁc gene and therefore detailed knowledge regarding the genes contributing to complex traits and dis-
eases remains elusive. The functional role of GWAS-SNPs is also affected by linkage disequilibrium with
many variants on the same haplotype and sometimes in the same regulatory element almost equally likely
to mediate the effect.
Using ChIP-seq data on many transcription factors, we pinpointed genetic variants in HepG2 and HeLa-S3 cell
lines which show a genome-wide signiﬁcant difference in binding between alleles. We identiﬁed a collection
of 3713 candidate functional regulatory variantsmany of which are likely drivers of GWAS signals or genetic dif-
ference in expression. A recent study investigatedmany variants beforeﬁnding the functional ones at theGALNT2
locus, which we found in our genome-wide screen in HepG2. This illustrates the efﬁciency of our approach.





The aim of the human genome project was to learn more about
human biology in general and disease biology in particular. Both goals
have been met and in particular knowledge has increased dramatically
on gene variants that predispose to common diseases. The hope has
been that such knowledge could be used to improve health by preven-
tive measures or development of new drugs. It is well known that the
failure rate is high in the drug development pipeline but a recent
study [1] provides reason for hope. They showed that at the preclinical
stages few drugs are acting on targets supported by genetic studies
but among approved drugs such targets are signiﬁcantlymore prevalent
and they estimate that selecting targets based on genetics could double
the success rate in clinical development. For such a strategy to be suc-
cessful, knowledge has to be gained on the genes and pathwaysmediat-
ing the effect. A genome-wide association study (GWAS) points to a
region with associated genetic variants but rarely to a speciﬁc gene
and therefore detailed knowledge regarding the genes contributing to




trition, Center for Biosciences,
. This is an open access article underof the functional variants that drive the associations are located in reg-
ulatory elements and lead to different activity from the two alleles caus-
ing a difference in activity of the gene it regulates. The current GWAS
catalog [2] contains N16.000 SNPs associated to disease but to our
knowledge in b30 cases has a clear connection been made from the as-
sociated SNP to gene e.g. the ones regulating SORT1 [3], RFX6 [4] and
TOX3 [5]. This despite large efforts from international consortia, like
ENCODE [6], EpigenomeRoadmap andGTEx [7] [8], that have generated
basic information on functional DNA sequences and genes.
A GWAS identiﬁes SNPs with signiﬁcant association to a disease or
trait but due to linkage disequilibrium (LD) there can be many other
variants that are almost equally likely to mediate the effect. Such vari-
ants are rarely located in coding regions and the widely accepted as-
sumption is that most variants driving the association are located in a
regulatory element that affects the activity of a gene nearby. A second
problem is that regulatory elements like enhancers and silencers can
act on genes over a considerable distance making it difﬁcult to predict
target genes. However, if the functional regulatory element has been
identiﬁed, the regulated gene can be found experimentally by changing
the sequence e.g. by using CRISPR, by overexpressing or knocking down
transcription factors binding to the element or by studying 3 dimen-
sional interactions [9–11]. Finding the functional regulatory elements
is thus an important step towards deﬁning disease mechanisms.
It is therefore desirable to have a collection of candidate regulatory
variants andwe set out toﬁnd them in a systematicway. A common fea-
ture for the published functional variants is that the two alleles of the
driving SNP have different afﬁnity for a transcription factor (TF). Wethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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immunoprecipitation (ChIP) [12] and we [13] and others [14] have
shown that they can be detected in data from large-scale sequencing
(ChIP-seq). Herewe established the genetic variants in the hepatocellu-
lar carcinoma cell line HepG2 and used the public sequence from the
cervix cancer HeLa-S3 cell line. We then used public ChIP-seq data
from these cell lines on many transcription factors and deﬁned which
variants that show a genome-wide signiﬁcant difference in binding be-
tween alleles. This gave a collection of thousands of candidate functional
regulatory variants many of which are likely drivers of GWAS signals or
genetic difference in expression [15].
2. Material and methods
2.1. Genome sequencing
The HepG2 genomewas sequenced on IlluminaHiSeq to 10× cover-
age using 100 bp paired-end reads which in combination with reads
from published HepG2 experiments [6] and from our ChIP-seq experi-
ments and nucleosome sequencing [16] on the SOLiD system gave an
average 55× genome coverage. We aligned all Illumina reads using
BWA and SOLiD reads using BFAST and removed duplicate reads for
each sample. SNP calling was done using the GATK uniﬁed genotyper.
Sequencing, SNP calling and quality control is further described in Sup-
plementary materials.
2.2. ChIP-seq sequences
Raw ChiP-seq reads (.fastq) were obtained from the ENCODE project
database (ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/)
selecting all the TF ChIP-seq data available at the time of download for
HepG2 (data at Jul., 2012) and HeLa-S3 (Dec., 2013).
2.3. Genomic features
AS-SNPs collections were intersected and ﬁltered with several pub-
licly available databases: NHGRI GWAS catalog (Jan., 2014), collection
of signal artifact blacklisted ENCODE regions [6], 1000 Genomes SNPs
collection (1000 Genomes project, phase1_release_v3.20101123), liver
tissue eQTLs collections (http://www.ncbi.nlm.nih.gov/gtex/GTEX2/
gtex.cgi# and http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/). The ref-
erence genome (G1) used was the UCSC hg19 assembly based on theFig. 1. Graphical summary of the AS-SNP disGenome Reference Consortium Human genome build 37 (GRCh37)
but excluding random and unplaced contigs. The alternative genomes
(G2), when not available, were built for the different cell lines using
the FastaAlternateReferenceMaker GATK utility that generates an alter-
native reference sequence replacing the reference bases at variation
sites with the bases supplied by a cell-speciﬁc SNPs collection. The
sources for cell-speciﬁc SNPs collections and alternative genomes
were for HeLa-S3: NIHs dbGaP restricted access to hybrid assemblies
of haplotype A and B on GRCh37 scaffold and SNPs calls, and for
HepG2 SNP calls were made as described above.2.4. AS-SNPs selection pipeline
The bioinformatics pipeline to identify AS-SNPs is described in de-
tails in Cavalli et al. [17]. The main steps (see Fig. 1) are summarized
here for clarity:
(1) Alignment of ChIP-seq reads to the reference (G1) and alterna-
tive (G2) genome using ASAP (http://www.bioinformatics.babraham.
ac.uk/projects/ASAP/).
(2) Reads mapped speciﬁcally to G1 or G2 were counted at the het-
erozygous SNPs.
(3) To determinewhether the G1/G2 read counts differencewas sta-
tistically signiﬁcant a binomial testwas applied against the null hypoth-
esis of an equal G1:G2 coverage. After correcting for multiple testing
(Benjamini & Hochberg or FDR), AS-SNPs with P b 0.05 were selected.
(4) AS-SNPs were then intersected with the 1000 Genomes SNPs
collection in order to retrieve AFs.
(5) Extensive ﬁltering of the selected AS-SNPs was performed to
minimize the false positives where the difference in read count could
be inﬂuenced by the genomic abnormal location of the SNPs (centro-
meric or telomeric regions, blacklisted ENCODE regions or CNVs).
(6) Pruned AS-SNPs selections were ﬁnally intersected with collec-
tions of GWAS or eSNPs and SNPs in LD (r2 N 0.5) with GWAS or
eSNPs to select candidate functional AS-SNPs for experimental
validation.2.5. Cell cultures
HepG2 cells were cultured in RPMI 1640 medium supplemented
with 10% non-inactivated FBS, L-glutamine and a solution stabilized,
with 10,000 units penicillin and 10 mg streptomycin/mL, sterile-covery pipeline for the HepG2 cell line.
250 M. Cavalli et al. / Genomics 107 (2016) 248–254ﬁltered, BioReagent, suitable for cell culture (Sigma-Aldrich) at 37 °C
with 5% CO2.
2.6. Construction of cloning plasmids and luciferase report assays
All the luciferase expression constructs were built based on
pGL4.23 from Promega. The ccdB expression cassette was inserted
into KpnI and EcoRV sites of pGL4.23 to construct pGL4.23-ccdB,
which was used as a basal vector to diminish false positive signal dur-
ing the cloning process. Genomic sequences surrounding AS-SNPs
were ampliﬁed by Phusion Hot Start Flex DNA polymerase (NEB)
using HepG2 genomic DNA as template (see Table S3). The ampliﬁed
fragments were puriﬁed by QIAquick Gel Extraction Kit (QIAGEN)
and inserted upstream of the minimal promoter sequence of pGL4.23
by SLiCE cloning methods [18]. To get both of the alleles of all the
AS-SNPs tested, multiple individual clones were picked up and sub-
jected to Sanger sequencing. HepG2 cells were transfected one day
after plating with approximately 90% conﬂuence in 96-well plate. All
the transfection reactions were carried out with X-tremeGENE HP
DNA transfection reagent (Roche). Each well was transfected with
100 ng of ﬁreﬂy luciferase reporter vector harboring respective AS-
SNPs alleles together with 1 ng of renilla luciferase reporter vector
pGL4.74, which was used to normalize the transfection and lysis efﬁ-
ciency. Twenty-four hours after transfection, the cells were harvested
and lysed in 1X passive lysis buffer (Promega) on a rocking platform
for 45 min at room temperature. Fireﬂy and luciferase activity were
measured by Dual-Luciferase® Reporter (DLR™) Assay System
(Promega) on an Inﬁnite® M200 pro reader (TECAN) following in-
structions provided by the manufacturer. The ratios of ﬁreﬂy luciferase
activity to renilla luciferase activity were calculated and expressed as
Relative Luciferase Units (RLU) in the ﬁgures. All data came from four
to six replicate wells, and p-values comparing RLU difference between
AS-SNPs alleles were calculated using two-tailed t-test.
3. Results
3.1. Sequence and allele-speciﬁc signals in HepG2 and HeLaS3 cell lines
We sequenced the genomes of the liver cell line HepG2 and
established that the allele calls were reliable using a genotyping array
and downloaded public data on the genome sequence of the HeLa-S3
cervix cancer cell line [19]. The ENCODE project has generated ChIP-
seq data for 55 and 57 TFs respectively from these cell lines and this
data was downloaded. We used the Allele Speciﬁc Alignment Pipeline
(ASAP) (http://www.bioinformatics.babraham.ac.uk/projects/ASAP/)
to align the reads to the reference (G1) and alternative (G2) alleles, re-
spectively. We counted the number of reads mapping to the G1 and G2
alleles at all heterozygous positions and those with a genome-wide sta-
tistically signiﬁcant difference in the number of reads were identiﬁed
after correcting for multiple testing and copy number variation (CNV)
(see Material and methods and Fig 1). We investigated the number of
reads mapping to the two genomes and found only small differences
and in line with previous studies [14] concluding that reference and
other alignment bias are well controlled for. We ﬁltered the data to re-
move potential false positives in repeated and ENCODE “blacklisted”
sequences.
In HepG2 we found 3001 SNPs with an allele-speciﬁc signal (AS-
SNP) and 712 in HeLaS3 cells. Only 34 AS-SNPs were shared between
the cells. This indicates that many regulatory elements are unique to
each cell and that common elements rarely show functional genetic
variation.
To validate the allele speciﬁc binding results from ChIP-seq, we
tested 39 AS-SNPs detected in HepG2 in luciferase assays (see Material
and methods). The AS-SNPs were either 1) randomly chosen AS-SNPs
with common AF or 2) AS-SNPs associated to expression or 3) GWAS
traits as explained below. An allele speciﬁc difference in activity wasveriﬁed for 27/39 (69%) of the AS-SNPs (Fig. 2). We also tested 9 SNPs
without a signiﬁcant difference in ChIP-seq reads numbers between al-
leles and in no casewas there a difference in activity.We concluded that
variants considered to be AS-SNPs according to our deﬁnition are highly
likely to be functional based on their location at regulatory elements,
difference in TF binding between alleles in ChIP-seq and validation in
functional tests such as luciferase assays.3.2. AS-SNPs associated to disease and gene expression
Not all entries in theGWAS catalog can have amolecular explanation
in the cells we study here. Genetic predisposition that could be medi-
ated by the cells investigated are for example metabolic diseases for
HepG2, and diseases of cervix for HeLaS3 (Table S1). We therefore
searched the GWAS catalog for these traits. The SNP with the strongest
association (GWAS top hit) was collected from the catalog and SNPs in
high (r2 N 0.8) or more relaxed (r2 N 0.5) LD were identiﬁed and
intersected with the collection of AS-SNPs. For 24 liver speciﬁc traits,
we found 69uniqueAS-SNPs thatwere candidates to explain GWAS sig-
nals with only 3 being the particular SNP reported in the GWAS catalog
and the other 66 were in the deﬁned LD intervals (Table 1, Fig. 3A and
Table S5). We grouped the SNPs in 1 Mb loci and found candidate func-
tional SNPs at 37 unique loci in HepG2.
Less cervical cancer speciﬁc traits are available in the GWAS catalog
so we compared the list of AS-SNPs in HeLa-S3 cells to the full GWAS
SNP collection (Fig. 3A and Table S8) as reported below.
We also observed a pattern where several GWAS-SNPs were associ-
ated to the sameAS-SNPwhich is compatiblewith the fact that GWAS in
different populations often show strongest association to different SNPs
(Fig 3A andB).We also found that several AS-SNPswere detected at one
locus e.g. seven SNPs located in different regulatory elements at the
SLC7A5 gene associated to blood metabolite levels (Table S5). This sug-
gests that SNPs at distinct regulatory elements could regulate activity of
the same gene, which is supported by recent data [20,21].
Furthermore, we took the top hits from thewhole GWAS catalog in-
cluding SNPs in LD (r2 N 0.5) and compared to the list of AS-SNPs. In this
wide search we found 337 AS-SNPs (Tables S6 and S8) and some of
themmay be functional due to pleiotropic effects.We found novel puta-
tive functional variants that may explain GWAS SNPs using liver tissue.
One example is the response to temozolomide, which is an alkylating
agent causing methylation of guanine residues that lead to single and
double-strand breaks in DNA and is used for the treatment of astrocy-
toma and glioblastoma, for which the top GWAS hits are located in
MGMT. This gene encodes a methylguanine-DNA methyltransferase in-
volved in DNA repair that is expressed in most tissues including the
liver. In HepG2 cells, the two AS-SNPs rs577227 and rs524545 are lo-
cated at regulatory elements 7 kb apart in the second intron of MGMT
and are thus good candidates to drive the effect of the GWAS top hit
rs477692.Most cells are likely to respond in the sameway to temozolo-
mide so the results from HepG2 may be representative of many cell
types.
We also searched for AS-SNPs that may explain eQTL signals i.e.
SNPs associated to gene expression in liver tissue [15]. We examined
whether AS-SNPs identiﬁed in HepG2 are better candidates to drive
the allelic difference in expression. We took SNPs in LD (r2 N 0.5)
with 3238 eSNPs for liver and investigated how many that are AS-
SNPs in HepG2. In HepG2 we found 4 AS-SNPs that are eSNPs, and
244 AS-SNPs that are in high LD with an eSNP (Table S7). The AS-
SNPs are located in regulatory elements and show evidence of
being functional so we think that they are good candidates to drive
the allele-speciﬁc expression variation. In the same way as for dis-
ease associated AS-SNPs we ﬁnd that only a small fraction of eSNPs
show tentative functional effect and that many more candidates
are in high LD. This suggests that the eSNPs themselves are not
good proxies as drivers of GWAS signals.
Fig. 2. Dual luciferase assays detecting a statistical signiﬁcant difference in activity between the alleles. (A) Numbers of tested variants in 3 different categories of AS-SNPs. Examples are
shown for common AS-SNPs (B) AS-SNPs in LD with eSNPs (C) or GWAS SNPs (D) and for non-AS-SNPs (E). Each dot represents a technical replica. Full scatter plots for all the 39 SNPs
tested are present in Supplementary material Fig. S1–S5. *** = P b 0.0001; ** = P b 0.001; * = P b 0.01; ns = not signiﬁcant.
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We found several AS-SNPs that may be causative in genetic associa-
tions. GWAS has founddifferent SNPs related to levels of HDL-Cwhich is
a quantitative trait for which low levels are strongly associated to coro-
nary artery disease.We found that the AS-SNP rs4846913 in the ﬁrst in-
tron of GALNT2 is in LD (1 N r2 N 0.777) in relation to several GWAS SNPs
and therefore a good candidate to explain the associations. We veriﬁed
the functional effect of rs4846913 and rs2144300 located in the same
regulatory element using luciferase and EMSA [22]. In a parallel project
Roman et al. thoroughly tested 25 candidate SNPs in luciferase assays
identifying rs4846913, rs2144300 as well as rs2281721 located nearby
as the functional variants mediating the allelic effect on GALNT2 [23].
Our approach allowed us to pinpoint the same regulatory elementwithout the need to screen many SNPs before arriving at the functional
one(s), emphasizing the precision and effectiveness of our strategy.
MERTK is a proto-oncogene and alleles of this gene are likely to pre-
dispose to Hepatitis C induced liver ﬁbrosis which shows genetic associ-
ation to rs4374383 [24] with 72 SNPs in high LD. Liver ﬁbrosis
predisposes to hepatocellular carcinoma suggesting that this pathway
might contribute to both diseases. It is not reasonable to make func-
tional tests of all 72 SNPs in the high-LD region. The AS-SNP
rs6726639 is in the 8th intron and rs13394651 in intron 7 are good can-
didates to drive the associations which need to be validated in separate
experiments.
ELOVL2 is a member of the elongase enzymes referred to as Elonga-
tion of very-long-chain fatty acids proteins (ELOVLs) that selectively
acts on polyunsaturated fatty acids (PUFAs). Several recent studies
Table 1
AS-SNPs detected in HepG2 associated to liver-speciﬁc GWAS traits.
GWAS cell speciﬁc associated traits Number of AS-SNPs in LD r2 N 0.8
(0.5)




% of reported loci with LD r2 N 0.8
AS-SNPs
Blood metabolite levels 10 (16) 5 (9) 107 4,7
HDL cholesterol 6 (8) 3 (4) 78 3,8
Triglycerides 5 (9) 4 (5) 42 9,5
Primary biliary cirrhosis 4 (5) 2 (2) 24 8,3
Liver enzyme levels (alkaline phosphatase) 4 (4) 2 (2) 14 14,3
Metabolic syndrome 3 (4) 2 (2) 34 5,9
Fibrinogen 3 (4) 2 (2) 23 8,7
Blood metabolite ratios 2 (3) 2 (3) 47 4,3
Warfarin maintenance dose 2 (2) 1 (1) 6 16,7
Metabolite levels 2 (3) 2 (3) 209 1,0
Hepatitis C induced liver ﬁbrosis 2 (3) 1 (1) 6 16,7
Cataracts in type 2 diabetes 2 (2) 1 (1) 2 50,0
Phospholipid levels (plasma) 2 (2) 1 (1) 35 2,9
Type 2 diabetes 1 (3) 1 (2) 133 0,8
Nonalcoholic fatty liver disease 1 (1) 1 (1) 38 2,6
Liver enzyme levels (gamma-glutamyl transferase) 1 (2) 1 (2) 24 4,2
Insulin-like growth factors 1 (1) 1 (1) 6 16,7
LDL cholesterol 1 (3) 1 (3) 59 1,7
Metabolic traits 0 (4) 0 (4) 94 0
Hepatitis B vaccine response 0 (1) 0 (1) 1 0
Drug-induced liver injury (amoxicillin-clavulanate) 0 (3) 0 (1) 2 0
Fasting insulin-related traits (interaction with BMI) 0 (1) 0 (1) 18 0
Liver enzyme levels 0 (1) 0 (1) 55 0
Homocysteine levels 0 (2) 0 (2) 24 0
⁎ Loci deﬁned as GWAS SNPs within 1 Mb regions.
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fatty acid species in vivo and determines the lipid proﬁle of PUFAs in the
whole body. Independent GWAS studies have reported that variants lo-
cated in the ELOVL2 gene were associated with levels of PUFAs.
Employing our AS-SNP pipeline, rs953413 and rs3798713 which show
allele bias in TFs binding in ChIP-seq reads were identiﬁed as likely can-
didates to mediate the effect.Fig. 3. AS-SNPs associated to GWAS SNPs. (A) Model representation of the networks of interact
the simplest scenario with one AS-SNP in LD with a GWAS SNP. The tables report the numbers
eQTL) SNPs or one GWAS (or eQTL) SNPs is in LDwith different AS-SNPs, or where GWAS (or e
rs953413 identiﬁed in HepG2 (orange) is in LDwith 8 different GWAS SNPs (cyan), one of whic
SNPs is presented in Fig. S6.4. Discussion
GWAS has successfully identiﬁed thousands of variants associated to
many diseases and traits. Despite large-scale efforts like the ENCODE
and the Epigenome Roadmap projects, progress has been slow in iden-
tifying the exact SNP that is driving the effect. Themostwidely accepted
approach in the search for regulatory variants relies on theions observed between AS-SNPs and GWAS (or eQTL) SNPs. The dotted red box highlights
of instances observed in each cell line where one AS-SNP is in LD with several GWAS (or
QTL) SNPs were also AS-SNPs. (B) Experimental example of interactions network. AS-SNP
h is an AS-SNP itself (green), associated to plasma lipid levels. The genomic location of the
253M. Cavalli et al. / Genomics 107 (2016) 248–254identiﬁcation of SNPs altering a TF binding motif. Several databases,
such as RegulomeDB [25] and HaploReg [26], have been built following
this conceptwith SNPs deﬁned as regulatory based on the accumulation
of genomics evidences like ChIP-seq signals from TFs and histone mod-
iﬁcations and overlap to speciﬁc TF bindingmotifs. The effect of a SNP on
a TF motif represent the core of several bioinformatics approaches,
among others sTRAP [27], which calculate the DNA binding afﬁnity
based on biophysical models or rSNP MAPPER [28], which score the ef-
fect of SNPs on TFBS on a large scale.
Several other pipelines (e.g. AlleleSeq [14], iASeq [29], ALEA [30])
have been developed to exploit RNA-seq and ChIP-seq datasets in
order to gather information about allele speciﬁc expression (ASE) and
binding (ASB).
In thisworkwe followed an approach based on the principle that the
information regarding the preferential binding of a TF to one allele is in-
trinsically “written” in the ChIP-seq reads of cell speciﬁc TFs. The ASB to
an allele, measured in terms of ChIP-seq reads density at heterozygous
positions, was used to isolate candidate regulatory SNPs regardless of
their direct alteration of a TF binding motif.
We therefore searched systematically for such events in two cell
lines and found thousands of candidate functional variants. Such vari-
ants located in GALNT2 have been characterized in detail by us [22] to
show their functionality. The efﬁcacy and quality of our genomic screen-
ing was further conﬁrmed by an independent elegant study by Roman
et al. where a labor intensive testing of 25 SNPs was necessary to iden-
tify the same regulatory variants. In another locus associated to Hepati-
tis C induced liver ﬁbrosis there are 72 SNPs in high LD that potentially
can drive the effect and at such loci a screening procedure clearly is
needed to prioritize which SNPs that should be tested experimentally.
We have found AS-SNPs in high LD to the GWAS SNPs that are likely
drivers of the effect.
The liver is an important organ where several biochemical events
unfold which can contribute tomany diseases and traits that are central
to the metabolism. Here we present a list of 3001 candidate functional
SNPs that are likely to contribute to inter-individual variation. In the
present study we investigate the allele-speciﬁc effect only at heterozy-
gous positions which according to the Hardy-Weinberg law is 33% of
variants that are common in the population. If ChIP-seq data was gener-
ated for additional cell lines or tissues a larger portion of common vari-
ation could be investigated for difference in TF binding.
The data we present here are important for several reasons. It pro-
vides a collection of candidate functional variants which can be inves-
tigated further for contribution to disease processes. The importance of
developing new strategies to pinpoint functional variants is exempli-
ﬁed by variants in the FTO gene which are associated to body mass
index [31]. Initially it was suspected that FTO itself was the culprit
but Claussnitzer et al. [32] showed that in one regulatory element
rs1421085 disrupts a motif for the repressor ARID5B leading to dou-
bling of expression of IRX3 and IRX5 located 516 and 1164 kb away.
Such information is crucial for a detailed understanding of disease pro-
cesses. Since drugs acting on genetically supported targets are twice as
likely to work compared to drugs acting on other targets this informa-
tion will also aid pharmaceutical companies in developing new
therapies.
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